OptiNose

OptiNose — FY2023 Earnings Presentation

19 slides from OptiNose's earnings presentation, Mar 7, 2024

  1. Slide 1: Building a Leading ENT / Allergy Specialty Company

    Building a Leading ENT / Allergy Specialty Company C o r p o r a t e P r e s e n t a t i o n M a r c h 7 , 2 0 2 4 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this

  3. Slide 3: Key Takeaways

    3 Key Takeaways Chronic sinusitis is a 10-fold market opportunity for XHANCE Successfully executed our 2023 strategy to prioritize the potential launch of XHANCE as the first-ever FDA approved drug treatment for CS sNDA target action date next week (March 16, 2024) Return to strong growth in 2024, i

  4. Slide 4: Successful Development of XHANCE Creates Multiple New Opportunities for Growth

    4 Successful Development of XHANCE as the First FDA-approved Drug Treatment for Chronic Sinusitis Creates Multiple New Opportunities for Growth Up to ~1 Million patients with nasal polyps (NP) are treated by specialty physicians in our current sales deployment $1B TAM $3B TAM Up to ~10 Million patie

  5. Slide 5: ReOpen Program Update

    optinose_ ——— ReOpen Program Update

  6. Slide 6: ReOpen Clinical Program – Anticipated Next Steps and Recent Highlights

    6 ReOpen Clinical Program – Anticipated Next Steps and Recent Highlights  PDUFA target action date is March 16, 2024  ReOpen Program results published January 18 in The Journal of Allergy and Clinical Immunology: In Practice – Efficacy of EDS-FLU for Chronic Rhinosinusitis: Two Randomized Controll

  7. Slide 7: Q4 and Full Year 2023 Performance

    Q4 and Full Year 2023 Performance

  8. Slide 8: 2023 Company Strategy

    8 2023 Company Strategy  For 2023, we focused on increasing business efficiency, maintaining profitable prescription volume and revenue, while preserving resources and capabilities needed in 2024 to launch the new Chronic Sinusitis indication into our ENT/Allergy specialist audience: ‒ Reduced both

  9. Slide 9: XHANCE Prescriptions – Fourth Quarter 2023

    9 XHANCE Prescriptions – Fourth Quarter 2023 Changes to co-pay assistance reduced the number of unprofitable new and total prescriptions XHANCE New Prescriptions decreased 10% and Total Prescriptions decreased 14% 29.5 26.5 Q4 '22 Q4 '23 (in thousands) XHANCE New Prescriptions 92.5 79.5 Q4 '22 Q4 '2

  10. Slide 10: XHANCE Prescriptions – Full Year 2023

    10 XHANCE Prescriptions – Full Year 2023 XHANCE New Prescriptions decreased 2% and Total Prescriptions decreased 3% 117.6 115.3 Full Year 2022 Full Year 2023 (in thousands) XHANCE New Prescriptions 351.0 339.4 Full Year 2022 Full Year 2023 XHANCE Total Prescriptions (in thousands) Estimated based on

  11. Slide 11: Q4 and Full Year 2023 Financial Update

    Q4 and Full Year 2023 Financial Update

  12. Slide 12: Financial Review – Fourth Quarter 2023

    12 Financial Review – Fourth Quarter 2023 Changes to co-pay assistance drove an 11% increase in revenue per prescription SG&A plus R&D expenses decreased by ~$6 million from Q4 2022 to Q4 2023 and Q4 2023 XHANCE Net Revenues of $19.9 million exceed financial guidance $26.2 $20.2 Q4 '22 Q4 '23 ($M) S

  13. Slide 13: Financial Review – Full Year 2023

    13 Financial Review – Full Year 2023 Execution of our 2023 strategy yielded a more efficient business that outperformed guidance Full Year 2023 SG&A plus R&D expenses decreased by ~$38 million (31%) compared to FY 2022 XHANCE Net Revenues of $71.0 million exceeded financial guidance $122.9 $85.1 Ful

  14. Slide 14: 2024 Outlook

    optinose_ ——— 2024 Outlook

  15. Slide 15: Q1 and Full Year 2024 Financial Guidance

    15 Q1 and Full Year 2024 Financial Guidance  XHANCE Net Revenue ‒ Q1 2024 expected to be approximately ~$13 million  XHANCE Average Net Revenue per Prescription ‒ FY 2024 expected to be approximately $220

  16. Slide 16: Closing Remarks

    optinose_ ——— Closing Remarks

  17. Slide 17: Key Takeaways

    17 Key Takeaways Chronic sinusitis is a 10-fold market opportunity for XHANCE Successfully executed our 2023 strategy to prioritize the potential launch of XHANCE as the first-ever FDA approved drug treatment for CS sNDA target action date next week (March 16, 2024) Return to strong growth in 2024,

  18. Slide 18: Investor Relations – Optinose Investor Contact

    18 Investor Relations – NASDAQ: OPTN Optinose Investor Contact Jonathan Neely, VP, Investor Relations and Business Development 267-521-0531 [email protected] As of December 31, 2023: – $73.7 million in cash – Debt: $130 million – 112 million common shares o/s – 46 million options, warrants & RS

  19. Slide 19: Building a Leading ENT / Allergy Specialty Company

    Building a Leading ENT / Allergy Specialty Company C o r p o r a t e P r e s e n t a t i o n M a r c h 7 , 2 0 2 4

Optinose — FY2023 Earnings Presentation on 6ix